Filing Flows › Angiodynamics (ANGO) › Q3 FY26
Angiodynamics (ANGO) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Apr 2, 2026
Angiodynamics (ANGO) reported revenue of $78.4M for the third quarter fiscal 2026 (Q3 FY26), +9% from a year earlier and -1% from the quarter before. Operating margin was -16.5%, net loss $8.1M (10.3% of revenue).
Angiodynamics, Q3 FY26: revenue $78.4M (+9% year over year), operating margin -16.5%, net loss $8.1M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78.4M | -1% | +9% |
| Operating profit | −$13.0M | — | — |
| Net earnings | −$8.1M | — | — |
| Operating cash flow | −$3.1M | -167% | — |
What changed
Revenue was $78.4M in Q3 FY26, up 9% year over year and down 1% from the previous quarter. Med Device was the largest line at 52% of revenue. Med Tech added $5.9M year over year (up 19%), 93% of the total change.
Gross margin was 52.9%, down 1.1 points from Q3 FY25. Operating costs exceeded revenue by $13.0M, an operating margin of -16.5%. Operating expenses grew 11% against revenue growth of 9%. The fastest-growing cost line was Other operating costs (+55%). The quarter ended with a net loss of $8.1M, wider than the previous quarter's $6.3M loss. Non-operating items added $4.9M, -60% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.1M. Non-cash charges added back $5.6M of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $3.3M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$4.1M.
Questions
What was Angiodynamics' revenue in the third quarter fiscal 2026?
Angiodynamics (ANGO) reported revenue of $78.4M for the third quarter fiscal 2026 (Q3 FY26), +9% from a year earlier and -1% from the quarter before.
Was Angiodynamics profitable in the third quarter fiscal 2026?
Operating loss was $13.0M (-16.5% of revenue) and net loss $8.1M.
Source: Angiodynamics 10-Q on SEC EDGAR.